公开(公告)号：US20070186295A1

公开(公告)日：2007-08-09

申请号：US11657313

申请日：2007-01-24

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/00 ,  A61K48/00 ,  C07K14/82 ,  C07K16/30

CPC分类号： C07K16/32 ,  A61K39/0011 ,  C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  G01N33/57423 ,  G01N33/57492 ,  G01N33/6884

摘要： Surprisingly, the present inventors have discovered that expression of TAT-036 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-036 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-036 expression or activity, comprising: contacting a candidate compound with a TAT-036 and detecting the presence or absence of binding between said compound and said TAT-036, or detecting a change in TAT-036 expression or activity. Methods are also included for the identification of compounds that modulate TAT-036 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-036 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-036蛋白的表达与癌相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-036与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-036表达或活性的化合物的方法，其包括：使候选化合物与TAT-036接触并检测所述化合物与所述TAT-036之间是否存在结合，或 检测TAT-036表达或活性的变化。 还包括用于鉴定调节TAT-036表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-036表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070220620A1

公开(公告)日：2007-09-20

申请号：US11700590

申请日：2007-01-31

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K48/00 ,  C07K16/30 ,  C07K14/82 ,  C12P21/06

CPC分类号： G01N33/57423 ,  A61K39/00 ,  C07K14/4748 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/73 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Surprisingly, the present inventors have discovered that expression of TAT-046 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-046 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-046 expression or activity, comprising: contacting a candidate compound with a TAT-046 and detecting the presence or absence of binding between said compound and said TAT-046, or detecting a change in TAT-046 expression or activity. Methods are also included for the identification of compounds that modulate TAT-046 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-046 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-046蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-046与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-046表达或活性的化合物的方法，包括：使候选化合物与TAT-046接触并检测所述化合物与所述TAT-046之间是否存在结合，或 检测TAT-046表达或活性的变化。 还包括用于鉴定调节TAT-046表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-046表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070106065A1

公开(公告)日：2007-05-10

申请号：US11344933

申请日：2006-01-31

申请人： Paul Kearney ,  Heather Butler ,  Navdeep Jaitly ,  Sajani Swamy ,  Lyes Hamaidi ,  Marcelo Filgueira ,  Pierre Thibault ,  Denis Faubert ,  Daniel Chelsky ,  Joel Lanoix ,  Sylvain Brunet ,  Kevin Eng ,  Frank Aguilera ,  John Tsang ,  Michael Hu ,  Joachim Ostermann ,  Marguerite Boulos

发明人： Paul Kearney ,  Heather Butler ,  Navdeep Jaitly ,  Sajani Swamy ,  Lyes Hamaidi ,  Marcelo Filgueira ,  Pierre Thibault ,  Denis Faubert ,  Daniel Chelsky ,  Joel Lanoix ,  Sylvain Brunet ,  Kevin Eng ,  Frank Aguilera ,  John Tsang ,  Michael Hu ,  Joachim Ostermann ,  Marguerite Boulos

IPC分类号： C07K14/82 ,  C07K16/30 ,  C12P21/06 ,  A61K39/395 ,  A61K39/00 ,  C12P21/08 ,  C12P21/04

CPC分类号： C07K14/82 ,  C07K14/4748 ,  C07K16/3046

摘要： Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity. Methods are also included for the identification of anti-cancer compounds and compounds that modulate TAT-001 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-001 expression or activity.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-001蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-001与异常发育和生长有关，可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-001表达或活性的化合物的方法，包括：使候选化合物与TAT-001接触并检测所述化合物与所述TAT-001之间是否存在结合，或 检测TAT-001表达或活性的变化。 还包括用于鉴定调节TAT-001表达或活性的抗癌化合物和化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-001表达或活性的变化。

公开(公告)号：US20070269434A1

公开(公告)日：2007-11-22

申请号：US11700378

申请日：2007-01-31

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A61K39/395 ,  A61K48/00 ,  C07H21/00 ,  C07K16/18 ,  C12N5/06 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Surprisingly, the present inventors have discovered that expression of TAT-041 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-041 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-041 expression or activity, comprising: contacting a candidate compound with a TAT-041 and detecting the presence or absence of binding between said compound and said TAT-041, or detecting a change in TAT-041 expression or activity. Methods are also included for the identification of compounds that modulate TAT-041 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-041 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-041蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-041与异常发育和生长相关，并且可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了用于鉴定抑制TAT-041表达或活性的化合物的方法，其包括：使候选化合物与TAT-041接触并检测所述化合物与所述TAT-041之间是否存在结合，或 检测TAT-041表达或活性的变化。 还包括用于鉴定调节TAT-041表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-041表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192886A1

公开(公告)日：2007-08-16

申请号：US11699785

申请日：2007-01-30

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  G01N33/574 ,  C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  A61K39/00 ,  A61K48/00

CPC分类号： G01N33/57423 ,  A61K39/00 ,  C07K14/4748 ,  C07K16/32 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-044 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-044 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-044 expression or activity, comprising: contacting a candidate compound with a TAT-044 and detecting the presence or absence of binding between said compound and said TAT-044, or detecting a change in TAT-044 expression or activity. Methods are also included for the identification of compounds that modulate TAT-044 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-044 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-044蛋白的表达与癌症相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-044与异常发育和生长有关，可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了用于鉴定抑制TAT-044表达或活性的化合物的方法，其包括：使候选化合物与TAT-044接触并检测所述化合物与所述TAT-044之间是否存在结合，或 检测TAT-044表达或活性的变化。 还包括用于鉴定调节TAT-044表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-044表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192885A1

公开(公告)日：2007-08-16

申请号：US11698734

申请日：2007-01-26

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82 ,  C07K16/30 ,  A61K39/00

CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/57423 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-039 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-039 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-039 expression or activity, comprising: contacting a candidate compound with a TAT-039 and detecting the presence or absence of binding between said compound and said TAT-039, or detecting a change in TAT-039 expression or activity. Methods are also included for the identification of compounds that modulate TAT-039 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-039 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-039蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-039与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-039表达或活性的化合物的方法，包括：使候选化合物与TAT-039接触，并检测所述化合物与所述TAT-039之间是否存在结合，或 检测TAT-039表达或活性的变化。 还包括用于鉴定调节TAT-039表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-039表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192884A1

公开(公告)日：2007-08-16

申请号：US11698245

申请日：2007-01-25

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/395 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30 ,  A61K48/00

CPC分类号： G01N33/57423 ,  C07K14/4748 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/57492 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人吃惊的是，本发明人已经发现，人类患者中TAT-038蛋白的表达与癌相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-038与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-038表达或活性的化合物的方法，其包括：使候选化合物与TAT-038接触并检测所述化合物与所述TAT-038之间是否存在结合，或 检测TAT-038表达或活性的变化。 还包括用于鉴定调节TAT-038表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-038表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070180545A1

公开(公告)日：2007-08-02

申请号：US11655859

申请日：2007-01-19

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K48/00 ,  C12P21/06 ,  A61K39/395 ,  A61K39/00

CPC分类号： G01N33/57423 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/3023 ,  C07K2317/34 ,  C07K2317/73 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-031 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-031 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-031 expression or activity, comprising: contacting a candidate compound with a TAT-031 and detecting the presence or absence of binding between said compound and said TAT-031, or detecting a change in TAT-031 expression or activity. Methods are also included for the identification of compounds that modulate TAT-031 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-031 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-031蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-031与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-031表达或活性的化合物的方法，包括：使候选化合物与TAT-031接触，并检测所述化合物与所述TAT-031之间是否存在结合，或 检测TAT-031表达或活性的变化。 还包括用于鉴定调节TAT-031表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-031表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20100183630A1

公开(公告)日：2010-07-22

申请号：US11922881

申请日：2006-06-29

申请人： Marcelo Filgueira ,  Daniel Chelsky ,  Joel Lanoix ,  Kevin Eng ,  Pierre Thibault ,  Denis Faubert ,  Navdeep Jaitly ,  Sylvain Brunet ,  Frank R.M. Aguilera ,  John S.-C. Tsang ,  Michael Hu ,  Joachim B. Ostermann ,  Marguerite Boulos ,  Paul E. Kearney ,  Heather Butler ,  Sajani Swamy ,  Lyes Hamaidi

发明人： Marcelo Filgueira ,  Daniel Chelsky ,  Joel Lanoix ,  Kevin Eng ,  Pierre Thibault ,  Denis Faubert ,  Navdeep Jaitly ,  Sylvain Brunet ,  Frank R.M. Aguilera ,  John S.-C. Tsang ,  Michael Hu ,  Joachim B. Ostermann ,  Marguerite Boulos ,  Paul E. Kearney ,  Heather Butler ,  Sajani Swamy ,  Lyes Hamaidi

IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  G01N33/574 ,  A61P35/04

CPC分类号： G01N33/57419 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/4748 ,  G01N2500/04

摘要： Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-005蛋白的表达与癌症相关，并且过度表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-005与异常发育和生长相关，并且可用作鉴定抗癌药物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-005表达或活性的化合物的方法，包括：使候选化合物与TAT-005接触并检测所述化合物与所述TAT-005之间是否存在结合，或 检测TAT-005表达或活性的变化。 还包括用于鉴定调节TAT-005表达或活性的化合物的方法，包括：向细胞或细胞群体施用化合物，并检测TAT-005表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192887A1

公开(公告)日：2007-08-16

申请号：US11699833

申请日：2007-01-30

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/395 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30 ,  A61K48/00

CPC分类号： C07K14/4748 ,  C07K14/705 ,  G01N33/57423

摘要： Surprisingly, the present inventors have discovered that expression of TAT-042 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-042 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-042 expression or activity, comprising: contacting a candidate compound with a TAT-042 and detecting the presence or absence of binding between said compound and said TAT-042, or detecting a change in TAT-042 expression or activity. Methods are also included for the identification of compounds that modulate TAT-042 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-042 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-042蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-042与异常发育和生长相关，并且可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了鉴定抑制TAT-042表达或活性的化合物的方法，包括：使候选化合物与TAT-042接触，并检测所述化合物与所述TAT-042之间是否存在结合，或 检测TAT-042表达或活性的变化。 还包括用于鉴定调节TAT-042表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-042表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。